Related Experiment Videos
[Acute coronary syndrome without ST-segment elevation. Current guidelines]
Mario Plebani1, Martina Zaninotto
1Dipartimento di Medicina di Laboratorio, Azienda Ospedaliera-Università, Padova. mario.plebani@sanita.padova.it
Insights
Coronary artery disease management is evolving. New guidelines emphasize cardiac troponins for risk stratification, improving diagnosis and treatment of unstable angina and myocardial infarction.
Area of Science:
- Cardiology
- Clinical Chemistry
Context:
- Coronary artery disease (CAD) is a leading cause of mortality in Western countries.
- Unstable angina and myocardial infarction without ST-segment elevation are frequent CAD manifestations.
Purpose:
- To summarize current evidence and clinical practice guidelines for CAD.
- To highlight the integration of cardiac troponins into risk stratification algorithms.
Summary:
- Recent European and American guidelines for CAD incorporate cardiac troponins.
- These guidelines address diagnosis, risk stratification, and treatment.
- Quality specifications for cardiac troponin assays are crucial for reliable results.
Impact:
- Improved risk stratification and clinical decision-making for CAD patients.
- Emphasizes the need for high-reliability methods, quality control, and external quality assurance for troponin assays.
Abstract:
Coronary-artery disease is the leading cause of death in western countries. Unstable angina and myocardial infarction without ST-segment elevation are now recognized as among the most frequent and important clinical manifestations of coronary-artery disease. The European and American professional societies have released guidelines on diagnosis, risk stratification and treatment of these disorders. These guidelines summarise current evidences and translate them in clinical practice. Most important changes relate to the inclusion of troponins into the risk stratification algorithm. In addition, some guidelines released by scientific committees of the laboratory area further define the quality specifications for cardiac troponin assays. Powerful tests, such as cardiac troponins, on which critical decisions will rest need highly reliable methods, quality control and external quality assurance schemes.